Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M, Liedes O, Vara S, Haveri A, Pöysti S, Kolehmainen P, Maljanen S, Huttunen M, Reinholm A, Lundberg R, Skön M, Österlund P, Melin M, Hänninen A, Hurme A, Ivaska L, Tähtinen PA, Lempainen J, Kakkola L, Jalkanen P, Julkunen I. Belik M, et al. Front Immunol. 2023 Jan 23;14:1099246. doi: 10.3389/fimmu.2023.1099246. eCollection 2023. Front Immunol. 2023. PMID: 36756112 Free PMC article.
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, Tähtinen PA, Ivaska L, Maljanen S, Reinholm A, Belik M, Smura T, Häkkinen HK, Ortamo E, Kantele A, Julkunen I, Lempainen J, Kakkola L. Jalkanen P, et al. Among authors: belik m. Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9. Microbiol Spectr. 2022. PMID: 35262410 Free PMC article.
Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
Belik M, Jalkanen P, Lundberg R, Reinholm A, Laine L, Väisänen E, Skön M, Tähtinen PA, Ivaska L, Pakkanen SH, Häkkinen HK, Ortamo E, Pasternack A, Ritvos MA, Naves RA, Miettinen S, Sironen T, Vapalahti O, Ritvos O, Österlund P, Kantele A, Lempainen J, Kakkola L, Kolehmainen P, Julkunen I. Belik M, et al. Nat Commun. 2022 May 5;13(1):2476. doi: 10.1038/s41467-022-30162-5. Nat Commun. 2022. PMID: 35513437 Free PMC article.
Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.
Reinholm A, Maljanen S, Jalkanen P, Altan E, Tauriainen S, Belik M, Skön M, Haveri A, Österlund P, Iakubovskaia A, Pasternack A, Naves RA, Ritvos O, Miettinen S, K Häkkinen H, Ivaska L, Tähtinen PA, Lempainen J, Kantele A, Kakkola L, Julkunen I, Kolehmainen P. Reinholm A, et al. Among authors: belik m. Commun Med (Lond). 2024 Feb 23;4(1):28. doi: 10.1038/s43856-024-00457-3. Commun Med (Lond). 2024. PMID: 38396065 Free PMC article.
Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity.
Belik M, Reinholm A, Kolehmainen P, Heroum J, Maljanen S, Altan E, Österlund P, Laine L, Ritvos O, Pasternack A, Naves RA, Iakubovskaia A, Barkoff AM, He Q, Lempainen J, Tähtinen PA, Ivaska L, Jalkanen P, Julkunen I, Kakkola L. Belik M, et al. Front Immunol. 2024 Nov 21;15:1494432. doi: 10.3389/fimmu.2024.1494432. eCollection 2024. Front Immunol. 2024. PMID: 39640263 Free PMC article.
The comprehensive SARS-CoV-2 'hijackome' knowledge base.
Huuskonen S, Liu X, Pöhner I, Redchuk T, Salokas K, Lundberg R, Maljanen S, Belik M, Reinholm A, Kolehmainen P, Tuhkala A, Tripathi G, Laine P, Belanov S, Auvinen P, Vartiainen M, Keskitalo S, Österlund P, Laine L, Poso A, Julkunen I, Kakkola L, Varjosalo M. Huuskonen S, et al. Among authors: belik m. Cell Discov. 2024 Dec 9;10(1):125. doi: 10.1038/s41421-024-00748-y. Cell Discov. 2024. PMID: 39653747 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
17 results